Navigation Links
DATATRAK Signs 6 Year Study with New Device Client
Date:10/7/2009

CLEVELAND, Oct. 7 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of a new client with the award of a study for evaluating the use of a thoracic stent graft in aneurysm repair. This six year, US-based study will seek to advance the use of minimally invasive surgical techniques for thoracic aortic aneurysms.

"DATATRAK is excited to work with the leading global provider of innovative devices for the treatment of peripheral vascular disease," said Laurence Birch, DATATRAK's Chairman of the Board. "We look forward to a long and prosperous relationship with this new client."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK to Present at 2009 SCDM Annual Conference
2. DATATRAK eClinical(TM) Supports Multifaceted Studies
3. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
4. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
5. DATATRAK International Reports First Quarter Results for 2008
6. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
7. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
8. Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)
9. Sosei Assigns AD 923 Assets to Pharmasol
10. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
11. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... PUNE, India , December 5, 2016 /PRNewswire/ ... Market Research, titled, "Global Cancer Biomarkers Market - Global Opportunity ... biomarkers market is projected to reach $15,737 million by 2022 ... from 2016 to 2022. Omic technologies segment accounted for more ... expected to maintain its dominance during the forecast period. ...
(Date:12/5/2016)... --  TrainerMD , the first HIPAA compliant software collaboration platform for ... Styku . Styku, a California -based ... users world-class, real-time 3D body scanning and analysis. Together with its ... hear and feel their health like never before. ... , , ...
(Date:12/5/2016)...  CVS Health, the nation,s largest pharmacy innovation company, ... of 100 percent on the Corporate Equality Index (CEI) ... annual national benchmarking survey and report on corporate policies ... Human Rights Campaign Foundation. "Our company,s ... customers and suppliers bring to CVS Health," said ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for the ... active alerts and even taking an EKG from the watch while sharing these ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... to understand the scope of their EHS regulatory obligations and rapidly collect, share, ...
(Date:12/5/2016)... Angeles (PRWEB) , ... December 05, 2016 , ... What: ... feed of the North Pole to our patients – using a video monitor and ... video. The hospital will transform the Auditorium into a Christmas Wonderland, which is where ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
Breaking Medicine News(10 mins):